Blockchain Registration Transaction Record

Ace Therapeutics Launches Preclinical Hematology CRO Services

Ace Therapeutics announces integrated preclinical hematology CRO services for blood disorder drug development, including in vivo models and in vitro platforms for sickle cell disease, thalassemia, and more.

This news matters because blood disorders affect millions worldwide, and the development of effective therapies is often hindered by poor preclinical models. Ace Therapeutics' integrated services address this gap by providing more translatable, end-to-end solutions that can speed up the journey from discovery to clinic, potentially leading to faster approvals of new treatments for patients with conditions like sickle cell disease, thalassemia, and bone marrow failure.